Edesa Biotech (EDSA) said on Friday that it appointed Peter Weiler as chief financial officer at the immunotherapy company on May 1. Weiler will replace Stephen Lemieux, who is leaving to pursue other opportunities.
Weiler joins Edesa Biotech from privately held Exzell Pharma, where he was president since August 2018.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.